WO1993004055A3 - Compounds used for the inhibition of hiv-protease - Google Patents

Compounds used for the inhibition of hiv-protease Download PDF

Info

Publication number
WO1993004055A3
WO1993004055A3 PCT/US1992/005250 US9205250W WO9304055A3 WO 1993004055 A3 WO1993004055 A3 WO 1993004055A3 US 9205250 W US9205250 W US 9205250W WO 9304055 A3 WO9304055 A3 WO 9304055A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
hiv
protease
inhibition
hrv
Prior art date
Application number
PCT/US1992/005250
Other languages
French (fr)
Other versions
WO1993004055A2 (en
Inventor
Lester Arthur Dolak
Eric Peter Seest
Joyce Irma Cialdella
Grace P Li
Michael John Bohanon
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of WO1993004055A2 publication Critical patent/WO1993004055A2/en
Publication of WO1993004055A3 publication Critical patent/WO1993004055A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/22—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings
    • C07C305/24—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P11/00—Preparation of sulfur-containing organic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to new compounds, known compounds and new uses for those compounds. The compounds of this invention are comprised of tetronic acid type compounds, panosialin type compounds and virustomycin type compounds that are inhibitors of HIV protease. The invention further comprises the extraction, isolation, and purification of the compounds plus a method of treating a human cell system, including a patient possibly infected with a human retrovirus (HRV), to prevent or retard the further replication of the HRV in that human cell system or patient.
PCT/US1992/005250 1991-08-27 1992-06-29 Compounds used for the inhibition of hiv-protease WO1993004055A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75017991A 1991-08-27 1991-08-27
US750,179 1991-08-27

Publications (2)

Publication Number Publication Date
WO1993004055A2 WO1993004055A2 (en) 1993-03-04
WO1993004055A3 true WO1993004055A3 (en) 1993-04-29

Family

ID=25016825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/005250 WO1993004055A2 (en) 1991-08-27 1992-06-29 Compounds used for the inhibition of hiv-protease

Country Status (2)

Country Link
AU (1) AU2267992A (en)
WO (1) WO1993004055A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626178A1 (en) * 1993-05-17 1994-11-30 Ciba-Geigy Ag Use of inhibitors of HIV-protease for the treatment of tumorous diseases
AU7636894A (en) * 1993-09-17 1995-04-03 Upjohn Company, The Substituted tetronic acids useful for treating hiv and other retroviruses
ES2191095T3 (en) * 1995-03-20 2003-09-01 Upjohn Co USEFUL REPLACED TETRONIC ACIDS AGAINST HIV AND OTHER RETROVIRUS.
EP4076437A1 (en) * 2019-12-16 2022-10-26 The Regents Of The University Of Michigan Inhibitors of mhc-i nef downmodulation for treating hiv

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202589A2 (en) * 1985-05-17 1986-11-26 Takeda Chemical Industries, Ltd. Pharmaceutical compositions containing ascorbic acid derivatives
JPH01308227A (en) * 1988-02-23 1989-12-12 Takeda Chem Ind Ltd Protease inhibitor
EP0365329A2 (en) * 1988-10-20 1990-04-25 Shionogi & Co., Ltd. Antibiotics active against Anaerobic Bacteria, their production and use, and strains of Enterobacter producing the same
EP0480624A1 (en) * 1990-10-11 1992-04-15 Merck & Co. Inc. Inhibitors of HIV protease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202589A2 (en) * 1985-05-17 1986-11-26 Takeda Chemical Industries, Ltd. Pharmaceutical compositions containing ascorbic acid derivatives
JPH01308227A (en) * 1988-02-23 1989-12-12 Takeda Chem Ind Ltd Protease inhibitor
EP0365329A2 (en) * 1988-10-20 1990-04-25 Shionogi & Co., Ltd. Antibiotics active against Anaerobic Bacteria, their production and use, and strains of Enterobacter producing the same
EP0480624A1 (en) * 1990-10-11 1992-04-15 Merck & Co. Inc. Inhibitors of HIV protease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPIL Week 9004, Derwent Publications Ltd., London, GB; AN 90-028213 & JP,A,1 308 227 (TAKEDA CHEMICAL IND. KK) cited in the application *

Also Published As

Publication number Publication date
WO1993004055A2 (en) 1993-03-04
AU2267992A (en) 1993-03-16

Similar Documents

Publication Publication Date Title
NO893400L (en) HIV PROTEASE INHIBITORS SUITABLE FOR TREATMENT OF AIDS.
AU2236688A (en) Covered retard forms
FR2615394B1 (en) USE OF CERTAIN 17-CETOSTEROIDS, POSSIBLY WITH AN IMMUNOMODULATOR AND / OR ANTIVIRAL AGENT, TO MANUFACTURE A MEDICAMENT FOR THE TREATMENT AND PREVENTION OF RETROVIRAL INFECTIONS
EP1273298A3 (en) Ritonavir in combination with an additional HIV protease inhibitor for treating aids
WO1992018123A3 (en) A method for inhibition of retroviral replication
MY138860A (en) Hiv protease inhibitors.
EP0270317A3 (en) Pharmaceutical compositions for the treatment of diseases caused by viruses
NO157146C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC, ACTIVE DERIVATIVES OF MORPHOLINYL-DAUNORBICIN AND MORPHOLINYL-DOCSORUBICIN.
SE8505121L (en) immuno
JPS5234935A (en) Medicinal composition
WO1993004055A3 (en) Compounds used for the inhibition of hiv-protease
JPS5218813A (en) Plasters for the relief of cutaneous diseases
DK531387A (en) 3-PROPENYLECE PHARMACEUTICAL DERIVATIVES, INTERMEDIATES FOR USE IN THE PREPARATION OF IT, AND PREPARATIONS CONTAINING THE PRESENT COMPOUNDS.
ZA991029B (en) Composition and methods for treatment of hiv infections.
WO1990013281A3 (en) Method of suppressing hiv infection
NO883047L (en) SUBSTITUTED BENZIMIDAZOLES, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEIR USE.
DK0859613T3 (en) Use of flupirtine for the prevention and treatment of diseases associated with damage to the hemopoietic cell system
DK608089D0 (en) ANTIVIRAL AGENT
DK284688D0 (en) BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS MEDICINAL PRODUCTS
NO871745D0 (en) BENZOTIAZINO DERIVATIVES, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICALS CONTAINING THEM AND THEIR USE.
DE3782594D1 (en) MEDICINES FOR TRANSDERMAL ADMINISTRATION OF NICORANDIL.
NO952234L (en) Transdermal administration system containing acetylsalicylic acid for antithrombosis therapy and cancer prevention
UA41338C2 (en) Method for inhibiting retroviral infection caused by human immunodeficiency virus (hiv), method for inhibiting human immunodeficiency virus (hiv)
WO1988007367A3 (en) Melatonin-derivatives for psychogenic stress and acute anxiety, and immuno-stimulant drugs
WO1988008707A3 (en) Rubradirin derivatives for treatment of hiv infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA